» Articles » PMID: 12529557

Searching for Alternative Sources of Postnatal Human Mesenchymal Stem Cells: Candidate MSC-like Cells from Umbilical Cord

Overview
Journal Stem Cells
Date 2003 Jan 17
PMID 12529557
Citations 278
Authors
Affiliations
Soon will be listed here.
Abstract

Mesenchymal stem cells (MSCs) have the capability for renewal and differentiation into various lineages of mesenchymal tissues. These features of MSCs attract a lot of attention from investigators in the context of cell-based therapies of several human diseases. Despite the fact that bone marrow represents the main available source of MSCs, the use of bone marrow-derived cells is not always acceptable due to the high degree of viral infection and the significant drop in cell number and proliferative/differentiation capacity with age. Thus, the search for possible alternative MSC sources remains to be validated. Umbilical cord blood is a rich source of hematopoietic stem/progenitor cells and does not contain mesenchymal progenitors. However, MSCs circulate in the blood of preterm fetuses and may be successfully isolated and expanded. Where these cells home at the end of gestation is not clear. In this investigation, we have made an attempt to isolate MSCs from the subendothelial layer of umbilical cord vein using two standard methodological approaches: the routine isolation of human umbilical vein endothelial cell protocol and culture of isolated cells under conditions appropriate for bone-marrow-derived MSCs. Our results suggest that cord vasculature contains a high number of MSC-like elements forming colonies of fibroblastoid cells that may be successfully expanded in culture. These MSC-like cells contain no endothelium- or leukocyte-specific antigens but express alpha-smooth muscle actin and several mesenchymal cell markers. Therefore, umbilical cord/placenta stroma could be regarded as an alternative source of MSCs for experimental and clinical needs.

Citing Articles

Characterization of Urine-Derived Stromal/Stem Cells from Healthy Dogs and Dogs Affected by Chronic Kidney Disease (CKD).

Lange-Consiglio A, Tagliasacchi F, Cremonesi F, Gusmara C, Pollera C, Scarpa P Animals (Basel). 2025; 15(2.

PMID: 39858242 PMC: 11758669. DOI: 10.3390/ani15020242.


Mesenchymal stem cell therapy in atherosclerosis: A bibliometric and visual analysis.

Cheng X, Li Y, Wang H, Zhang R, Fan K, Qi X World J Stem Cells. 2024; 16(12):1062-1085.

PMID: 39734478 PMC: 11669984. DOI: 10.4252/wjsc.v16.i12.1062.


The Combination of Chitosan-Based Biomaterial and Cellular Therapy for Successful Treatment of Diabetic Foot-Pilot Study.

Humenik F, Vdoviakova K, Kresakova L, Danko J, Giretova M, Medvecky L Int J Mol Sci. 2024; 25(15).

PMID: 39125958 PMC: 11313444. DOI: 10.3390/ijms25158388.


Healing the Ischaemic Heart: A Critical Review of Stem Cell Therapies.

Tonkin D, Yee-Goh A, Katare R Rev Cardiovasc Med. 2024; 24(4):122.

PMID: 39076280 PMC: 11273058. DOI: 10.31083/j.rcm2404122.


Stem Cell Therapy and Thiamine Deficiency-Induced Brain Damage.

Hazell A Neurochem Res. 2024; 49(6):1450-1467.

PMID: 38720090 DOI: 10.1007/s11064-024-04137-5.